Kornimate/medical-research-clean huggingface dataset:
left atrium substrate based ablation plus circumferential pulmonary vein isolation to treat chronic atrial fibrillation

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to determine whether left atrium substrate based ablation plus circumferential is effective in the treatment of persistent and long-standing atrial fibrillation.


Eligibility criteria:
inclusion criteria: all persistent or permanent af patients with refractory or intolerant to at least one class 1 or class 3 antiarrhythmic medication. exclusion criteria: 1. patients with paroxysmal af (self-terminating episodes lasting \< 7 day) 2. patients who have had a previous af ablation procedure 3. pregnancy

Keywords: atrial fibrillation catheter ablation mapping
hiccups and obstacles of e-learning among medical sudents

Conditions: Covid-19; E-learning; Medical Student

Summary: the covid-19 pandemic is the characterizing worldwide wellbeing emergency within recent memory. since its development in asia before the end of last year, the infection has spread to each mainland with the exception of antarctica. countries are dashing to moderate the spread of the illness by testing and treating patients, completing contact following, restricting travel, isolating residents, and dropping huge social occasions like games, shows, and educational institutes. as almost every institution was closed for the safety of human kind. all educational institutes were also closed for any kind of education. also, in pakistan all educational institutes were closed since march 2020. it was impossible to keep educational activities closed for long. in order to keep educational activities in working e-learning was introduced through out the world. as many other countries pakistan also started e-learning for all students.

a world is transitioning from physical classes to hybrid studies. pakistan is listed among third world country the availability of infra structure for hybrid study is not well developed, as consequence many hurdles and barriers are being faced by students, this has also been seen during covid-19 too. distance e-learning in medical education may represent a suitable alternative to traditional learning to deliver high-quality education. the availability of essential infrastructures and efficient institutional strategies represent a major challenge for integrating distance learning in medical education. during the pandemic, instructors and teaching staff were required to adapt quickly to the rapid transition in the education process and depend completely on the online platforms available, to deliver their courses, exams, and other required teaching and learning activities. while rapid transition to distance online learning was a mandatory and necessary action to ensure the learning continuity during the covid-19 pandemic, it was not always a smooth process, that posed many challenges for instructors, learners. distance e-learning is defined as using technology to deliver training, including technology supported learning either online, offline, or both. it is aimed at the effective construction of knowledge regarding individual experience, practice, and knowledge of the learners and students. internet-based learning, computer-based learning, virtual classrooms, and digital collaboration all represent different types of e-learning

Eligibility criteria:
inclusion criteria: all undergraduate medical students of pakistan. exclusion criteria: postgraduate medical students teaching faculty

Keywords: covid-19 obstacles screen time
tailoring upper limb exercise advice for people with parkinson disease

Conditions: Parkinson Disease; Upper Limb; Aerobic Exercise

Summary: the investigators will explore the impact of hand cycling, on hand function in people with parkinson's disease (pd). the study will compare the effects of two different hand cycling approaches-steady-state and interval efforts-on improving hand dexterity in people with pd. conducted as a clinical trial, it aims to understand if a single session of hand cycling can temporarily enhance hand function and if the nature of the exercise influences the benefit.

the purpose of this study is to examine the effects of hand cycling, an upper limb aerobic exercise, on hand function in individuals with parkinson's disease (pd). parkinson's disease affects motor skills, including hand dexterity, which can impede daily activities. while aerobic exercise is known to have benefits for people with pd, the specific impact of upper limb exercises like hand cycling on hand function is less studied. previous research suggests aerobic exercises can improve symptoms and motor function in pd. this study aims to fill the gap in understanding how hand cycling affects hand dexterity in pd. there is no placebo involved in this study as it compares two active intervention types: steady-state and high-intensity interval hand cycling. this is a block randomized parallel group clinical trial involving a single session of exercise intervention. participants will be randomly assigned to one of two groups: steady-state or high-intensity interval hand cycling. the study includes baseline assessments, the exercise intervention, and post-intervention assessments to evaluate changes in hand function. the primary endpoint is the time to complete the 9-hole pegboard test with the clinically more affected hand. secondary endpoints include changes in motor examination scores, finger tapping speed, and subjective measures of exercise perception. analysis of covariance will be used to compare the primary outcome between groups, accounting for baseline performance and clinical characteristics. the planned sample size is 20 people with pd, aiming to capture varied clinical expressions of the disease.

Eligibility criteria:
inclusion criteria: * adults over 19 with a clinical diagnosis of pd. exclusion criteria: * medical contraindication to aerobic exercise, such as unstable cardiovascular disease, or physical disability that precludes arm exercise. * individuals will be excluded if, upon screening with the canadian society for exercise physiology (csep) get active questionnaire and international physical activity questionnaire short form (ipaq-sf) a need for further evaluation before exercise is identified
improving biopsy experiences study for women

Conditions: Imaging Guided Breast Biopsy

Summary: the goal of this study is to examine whether a guided meditation intervention will reduce anxiety and distress as compared to a music intervention or radiologist supportive dialogue in women undergoing imaging-guided core needle breast biopsies. both the guided meditation and music interventions are administered through use of headphones during routine outpatient imaging-guided core needle breast biopsies. women in the guided meditation and music conditions will be given a cd with instructions for home practice. women complete follow-up questionnaires in the 12 months after biopsy. receipt of recommended follow-up care is examined for 60 months.


Eligibility criteria:
inclusion criteria: * 21 years old or older * undergoing imaging guided core needle biopsy * mammography or ultrasound breast imaging - reporting and data system(bi-rads) final assessment category 3,4a-c, or 5 * able to speak and read english * able to provide meaningful consent exclusion criteria: * significant hearing impairment

Keywords: breast biopsy anxiety
combining opioid addiction treatment services with care for infectious endocarditis

Conditions: Endocarditis, Bacterial; Opioid-use Disorder; Buprenorphine; Outpatient Parenteral Antibiotic Therapy

Summary: hospitalizations for severe infections associated with opioid use disorder (oud), such as infective endocarditis (ie), have doubled in the us over the past decade and are frequently prolonged and resource-intensive. once medically stabilized, persons with ie but without drug use typically enroll in outpatient parenteral antibiotic therapy (opat), while persons with ie and oud are kept in the hospital for the duration of therapy (often 6 weeks or more) largely due to concerns of ongoing drug use. unfortunately, hospitalization for ie with oud infrequently includes evidence-based medication-assisted treatment (mat) with buprenorphine or methadone to address the oud, despite the strong evidence that mat decreases illicit drug use and mortality. enrolling hospitalized persons with ie due to oud into comprehensive mat (i.e., buprenorphine + counseling) while inpatient, and providing an intensive transitional outpatient care program supporting mat, may support provision of outpatient iv antibiotic therapy and be cost effective. the primary aim of this pilot randomized clinical trial is to evaluate the equivalence of current practice plus buprenorphine (keeping patients with ie due to opioid use disorder in the hospital for the full duration of antibiotic treatment) compared to opat plus buprenorphine (discharge with outpatient treatment once medically stable).


Eligibility criteria:
inclusion criteria: * meeting oud by dsm-v criteria * have ie by duke's criteria * candidates for outpatient treatment with buprenorphine * accepting of buprenorphine treatment * anticipated to be discharged home after medically stabilized * requiring ≥ 2 weeks of iv antibiotic therapy * having ≥ 1 week of iv antibiotic therapy remaining at the time of medical readiness for discharge (as defined by the primary clinical team), * and providing informed consent. exclusion criteria: * presence of stroke or central nervous system involvement * clinically active embolic sequelae (e.g. pulmonary sepsis, mycotic aneurysms, splenic abscesses) * tv treated surgically or endovascularly (angiovac) * presence of osteomyelitis * fungal ie * patients who require inpatient physical rehabilitation determined by physical or occupational therapy assessment * current pregnancy * current severe methamphetamine, cocaine, alcohol or benzodiazepine use disorders by dsm-v criteria * currently enrolled in ongoing mat for oud * hypersensitivity or allergy to buprenorphine * chronic pain requiring opioids * class iii or iv heart failure * cirrhosis * end stage renal disease * other significant screening laboratory/medical/psychiatric/psychosocial condition that may prevent the volunteer from safely participating in the study in the opinion of the investigator (e.g. currently suicidal) * pending legal action that could interfere with study participation * living more than a 45-minute drive from uk given the intense outpatient component to the intervention.
clinical performance of a new daily disposable contact lens worn in an established contact lens wearing population

Conditions: Refractive Error; Myopia

Summary: this study seeks to evaluate the clinical and subjective performance of a new daily disposable soft contact lens.


Eligibility criteria:
inclusion criteria: 1. they are of legal age (17 years) and capacity to volunteer. 2. they understand their rights as a research subject and are willing to sign a statement of informed consent. 3. they are willing and able to follow the protocol. 4. they would be expected to attain at least 6/9 (20/30) in each eye with the study lenses. 5. they are able to wear contact lenses with a back vertex power of -1.00 to -6.00ds. 6. they have a maximum of 1.00d of refractive astigmatism (i.e. ≤ 1.00 dc). 7. they have successfully worn contact lenses within six months of starting the study. exclusion criteria: 1. they have an ocular disorder which would normally contra-indicate contact lens wear. 2. they have a systemic disorder which would normally contra-indicate contact lens wear. 3. they are using any topical medication such as eye drops or ointment. 4. they are aphakic. 5. they have had corneal refractive surgery. 6. they have any corneal distortion resulting from previous hard or rigid lens wear or has keratoconus. 7. they are pregnant or lactating. 8. they have grade 2 or greater of any of the following ocular surface signs: corneal oedema, corneal vascularisation, corneal staining, tarsal conjunctival changes or any other abnormality which would normally contraindicate contact lens wear. 9. they have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. hiv). 10. they have diabetes. 11. they have taken part in any other clinical trial or research, within two weeks prior to starting this study.
intermountain inpatient bilirubin decision accuracy study using smartphone-based measurements by picterus jaundice pro

Conditions: Neonatal Jaundice

Summary: the goal of this project is to evaluate the performance of picterus jaundice pro in an american population, including preterm and term newborns and pre- and post- phototherapy.

the purpose of this study is to compare serum bilirubin levels with non-invasive bilirubin measurements in neonates during the first 12 to 192 hours of life using the "picterus jaundice pro" smartphone application with a proprietary calibration card placed over the neonate's sternum. we will also validate the accuracy of picterus jaundice pro bilirubin measurements before and after phototherapy treatment.

Eligibility criteria:
inclusion criteria: * the patient is free of skin rash, bruising, or other medical conditions that can interfere with transcutaneous measurement * (preterm) \< = 35 weeks gestational age * (term) \> 35 weeks gestational age * the patient has not been excluded by pi discretion. exclusion criteria: * neonates will be excluded from participation if all four inclusion criteria listed above are not met.

Keywords: jaundice neonate phototherapy
the safety and efficacy of long-term treatment of pins stimulator system for patients with alzheimer's disease

Conditions: Alzheimer's Disease

Summary: purpose: the purpose of this clinical study is to verify the long term effectiveness and safety of a bilateral deep brain stimulation (dbs) produced by beijing pins medical co., ltd. as a treatment option for patients with cognitive, behavioral, and functional disability of alzheimer's disease.

other: deep brain stimulation implanted device subjects will then be instructed to apply pins deep brain stimulation device for 12 month.

Eligibility criteria:
inclusion criteria: 1. subject is aged 40 to 80 years old; 2. subject with ad diagnosed according to the criteria for probable ad as defined by the national institute of neurological disorders and stroke-alzheimer's disease and related disorders association (nincds-adrda); 3. subject have received the diagnosis of ad within the past 2 years; 4. subject have a cdr of 0.5 or 1.0; 5. score between 20 and 28 on the mini mental state examination 6. have been taking a stable dose of cholinesterase inhibitors for a minimum of 6 months. exclusion criteria: 1. patients with hearing impairment; 2. failures of important organs and in severe conditions 3. be reluctant or disabled to receive neuropsychological assessments; 4. participate in other clinical trial; 5. has a life expectancy of \< 1 year. 6. the investigator and/or enrollment review committee, would preclude participation in the study.

Keywords: alzheimer's disease
electrical stimulation of the dentate nucleus for upper extremity hemiparesis due to ischemic stroke

Conditions: Stroke

Summary: this clinical trial will evaluate if deep brain stimulation (dbs) is safe for the treatment of stroke and will help understand if dbs improves motor recovery for patients who continue to have significant impairment.

the proposed study is a safety and feasibility study intended to provide preliminary data to design a future pilot study. the objective of this study is to document the safety and patient outcomes of electrical stimulation of the dentate nucleus area for the management of chronic, moderate to severe upper extremity hemiparesis due to ischemic stroke.

Eligibility criteria:
key inclusion criteria: * one-time stroke that occurred 1-3 years ago (i.e. index stroke 12-36 months) * stroke due to a blocked blood vessel (i.e. unilateral mca stroke) * moderate to severe weakness in one arm (i.e. unilateral upper-extremity hemiparesis) key exclusion criteria: * seizures since time of stroke (i.e. seizures or seizure disorder) * unable to have an mri (i.e. contraindicated for mri)

Keywords: ischemic stroke deep brain stimulation dbs physical therapy rehab brain stimulation
effect of quadratus lumborum muscle energy technique in sacroilliac joint dysfunction.

Conditions: Sacroiliac Disorder

Summary: sacroiliac joint as a potential source of low back pain is an overlooked problem. yet, in the existing years there has been an increasing interest in sacroiliac joint as a pain originator and more attention is being paid into its assessment and treatment in the current literature. muscle imbalance due to postural dysfunction involves mainly gluteus medius and hamstring; however the role of quadratus lumborum working on compensatory mechanism and its treatment effect in the management of sacroiliac joint dysfunction is yet not discovered.

going through current literature, it is evident that sacroiliac joint dysfunction as a postural dysfunction is highly prevalent among adult population. this dysfunction due to major muscle imbalances if not treated timely can result in serious consequences later in life where it becomes the permanent dysfunction involving the major changes in the joint itself. muscle imbalance due to postural dysfunction involves mainly gluteus medius and hamstring; however the role of quadratus lumborum working on compensatory mechanism and its treatment effect in the management of sacroiliac joint dysfunction is yet not discovered. all patients will be assessed and screened by consultants as indicated and will refer to physiotherapy with diagnosed non- specific chronic back pain.patients will further be screened for sij dysfunction by physiotherapist.only those patients who fulfill the criteria of quadratus lumborum tightness \& gulteus medius weakness will randomly be selected and the sample of 70 will finally be selected for intervention.written consent form will be taken from all study participants.simple randomization technique will be used through "randomization main" software and randomization sheet will be generated. patients will be further be assigned equally into two groups as per randomization sheet.treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary. the selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention).

Eligibility criteria:
inclusion criteria: * • subjects with unilateral non-specific lbp * the subjects having at least 3 pain provocative tests of sij positive out of 5. * age 30-50 years. both male and female. * pain history greater than six weeks. * sij diagnostic scoring cut off point 4. * vas cut off point mild to moderate. exclusion criteria: * radiating pain with sensory or motor deﬁcits. * history of fracture or any spinal surgery * trauma * any dysfunction of hip or knee * any systemic disease. * pregnancy

Keywords: met, quadratus lumborum, sacroilliac joint
trial of bdc-1001 +/- pertuzumab in subjects with her2-positive metastatic breast cancer

Conditions: Metastatic Breast Cancer; HER2-positive Breast Cancer

Summary: this is an open-label, phase 2 study to evaluate preliminary anti-tumor activity, safety, tolerability, pharmacokinetics (pk), pharmacodynamics (pd), and immunogenicity of bdc-1001 administered as a single agent and in combination with pertuzumab in subjects with human epidermal growth factor receptor 2-positive (her2+) metastatic breast cancer (mbc) previously treated with trastuzumab deruxtecan (enhertu®).

eligible subjects will be randomly assigned in a 1:1 ratio to receive bdc-1001 as a single agent or bdc-1001 in combination with pertuzumab. within each treatment arm, a simon 2-stage design will be applied. subjects will receive study treatment (i.e., bdc-1001 or bdc-1001 in combination with pertuzumab) for up to 24 months after cycle 1 day 1 (c1d1), until disease progression, unacceptable toxicity, or withdrawal for any reason. bolt amended the protocol to transition any subjects still receiving bdc-1001 to continue receiving bdc-1001 in the maintenance phase. subjects remaining on bdc-1001 will continue to receive bdc-1001 until a criterion for discontinuation has been met.

Eligibility criteria:
key inclusion criteria: * histologically confirmed adenocarcinoma of the breast that is her2+ (ihc 3+ or gene amplification by ish or ngs). * have received 2 or more prior lines of anti-her2-directed therapies, at least 1 in the metastatic setting and including trastuzumab deruxtecan. * measurable disease as determined by recist v.1.1. * eastern cooperative oncology group (ecog) performance status of 0 or 1. * have life expectancy of greater than 12 weeks per the investigator. * all subjects must agree to have a biopsy prior to enrollment. if, in the judgment of the investigator, a biopsy is not safely accessible or clinically feasible an archival tumor tissue sample must be submitted in lieu of a freshly collected specimen. key exclusion criteria: * history of severe hypersensitivity to any ingredient of bdc-1001 or pertuzumab. * previous treatment with a small molecule tlr7/8 agonist or tlr7/8 agonist that has been conjugated to tumor-targeting antibody such as isacs within 12 months before starting study treatment. * impaired cardiac function or history of clinically significant cardiac disease. * human immunodeficiency virus (hiv) infection, active hepatitis b infection, or hepatitis c infection. * central nervous system metastases with the exception of disease that is asymptomatic, clinically stable, and has not required steroids for at least 28 days before starting study treatment.